Claims
- 1. An isolated S. pneumoniae surface associated Pneumo Protective Protein (PPP) having a molecular weight of about 20 kilo Daltons (kDa), wherein said molecular weight is determined using a 10-20% SDS-PAGE gel, or a fragment thereof; said PPP having the ability to reduce colonization of pneumococcal bacteria.
- 2. A PPP as defined in claim 1, wherein said PPP is a recombinant protein.
- 3. A PPP as defined in claim 2, said PPP having an isoelectric point of about 4.587.
- 4. A PPP as defined in claim 3, said PPP having a charge of about −14.214 at pH 7.
- 5. A PPP as defined in claim 1, said PPP having an amino acid sequence as depicted in SEQ ID NO: 5, or a fragment thereof.
- 6. A nucleic acid sequence encoding a PPP as defined in claim 1, wherein said nucleic acid sequence has a sequence as depicted in SEQ ID NO: 4, or a fragment thereof.
- 7. A nucleic acid as defined in claim 6 which is a cDNA.
- 8. An expression vector comprising a nucleic acid sequence encoding a PPP as defined in claim 1, wherein said sequence is operatively associated with an expression control sequence.
- 9. A vector as defined in claim 8, wherein said PPP has an isoelectric point of about 4.587.
- 10. A vector as defined in claim 9, wherein said PPP has a charge of about −14.214 at pH7.
- 11. An expression vector comprising a nucleic acid sequence encoding a PPP as defined in claim 5, wherein said sequence is operatively associated with an expression control sequence.
- 12. A vector as defined in claim 11, wherein said nucleic acid sequence has a sequence as sequence as depicted in SEQ ID NO: 4, or a fragment thereof.
- 13. A host cell transfected with the vector as defined in claim 8.
- 14. A host cell transfected with the vector as defined in claim 11.
- 15. A method for producing recombinant PPP which method comprises isolating said PPP produced by the host cells as defined in claim 13, wherein the host cells have been cultured under conditions that provide for expression of said PPP by said vector.
- 16. A method for producing recombinant PPP which method comprises isolating said PPP produced by the host cells as defined in claim 14, wherein the host cells have been cultured under conditions that provide for expression of said PPP by said vector.
- 17. A composition comprising a PPP as defined in claim 1 and a pharmaceutically acceptable carrier.
- 18. A composition comprising a PPP as defined in claim 5 and a pharmaceutically acceptable carrier.
- 19. A composition comprising a nucleic acid sequence encoding a PPP as defined in claim 6 and a pharmaceutically acceptable carrier.
- 20. A composition comprising the expression vector as defined in claim 8 and a pharmaceutically acceptable carrier.
- 21. A composition comprising the expression vector as defined in claim 11 and a pharmaceutically acceptable carrier.
- 22. A composition comprising the host cell as defined in claim 13 and a pharmaceutically acceptable carrier.
- 23. A composition comprising the host cell as defined in claim 14 and a pharmaceutically acceptable carrier.
- 24. An immunogenic composition comprising (i) a S. pneumoniae surface associated PPP having a molecular weight of about 20 kilo Daltons (kDa), wherein said molecular weight is determined using a 10-20% SDS-PAGE gel, or a fragment thereof; (ii) a pharmaceutically acceptable carrier; and (iii) optionally at least one adjuvant.
- 25. A composition as defined in claim 24, said PPP having an isoelectric point of about 4.587.
- 26. A composition as defined in claim 25, said PPP having a charge of about −14.214 at pH7.
- 27. A composition as defined in claim 24, said PPP having an amino acid sequence as depicted in SEQ ID NO: 5 or an immunogenic fragment thereof.
- 28. A composition as defined in claim 27, said PPP encoded by a nucleic acid sequence having a sequence as depicted in SEQ ID NO: 4, or an immunogenic fragment thereof.
- 29. A composition as defined in claim 24, wherein said composition elicits protective immunity from a disease caused by Streptococcus pneumoniae.
- 30. A composition as defined in claim 29, wherein said disease is selected from the group consisting of otitis media, rhinosinusitis, bacteremia, meningitis, pneumonia, and lower respiratory tract infection.
- 31. A composition as defined in claim 29, wherein said PPP comprises an amino acid sequence as depicted in SEQ ID NO: 5, or an immunogenic fragment thereof.
- 32. A composition as defined in claim 29, wherein said PPP is encoded by a nucleic acid sequence as depicted in SEQ ID NO: 4, or an immunogenic fragment thereof.
- 33. An immunogenic composition comprising (i) at least one expression vector encoding a PPP having a molecular weight of about 20 kDa, wherein said molecular weight is determined using a 10-20% SDS-PAGE gel; (ii) a pharmaceutically acceptable carrier; and (iii) optionally at least one adjuvant.
- 34. A composition as defined in claim 33, wherein said pneumococcal bacteria is Streptococcus pneumoniae.
- 35. A composition as defined in claim 34, wherein said composition elicits protective immunity from a disease caused by Streptococcus pneumoniae.
- 36. A composition as defined in claim 35, wherein said disease is selected from the group consisting of otitis media, rhinosinusitis, bacterenia, meningitis, pneumonia, and lower respiratory tract infection.
- 37. A composition as defined in claim 33, said PPP having an isoelectric point of about 4.582.
- 38. A composition as defined in claim 37, said PPP having a charge of about 14.214 at pH7.
- 39. A composition as defined in claim 33, wherein said expression vector comprises a nucleic acid sequence encoding an amino acid sequence as depicted in SEQ ID NO: 5, or an immunogenic fragment thereof.
- 40. A composition as defined in claim 33, wherein said expression vector comprises a nucleic acid sequence depicted in SEQ ID NO: 4, or an immunogenic fragment thereof.
- 41. A method of inducing an immune response in a mammal, said method comprising administering to said mammal an amount of a composition as defined in claim 24 effective to induce an immune response in said mammal.
- 42. A method of inducing an immune response in a mammal, said method comprising administering to said mammal an amount of a composition as defined in claim 27 effective to induce an immune response in said mammal.
- 43. A method of inducing an immune response in a mammal, said method comprising administering to said mammal an amount of a composition as defined in claim 33 effective to induce an immune response in said mammal.
- 44. A method of inducing an immune response in a mammal, said method comprising administering to said mammal an amount of a composition as defined in claim 39 effective to induce an immune response in said mammal.
- 45. A method of inducing an immune response in a mammal which is infected with pneumococcal bacteria, said method comprising administering to said mammal an amount of a compound effective to inhibit binding of an amino acid sequence as depicted in SEQ ID NO: 5 to induce said immune response in said mammal.
- 46. A method for screening for a compound which induces an immune response in a mammal infected with pneumococcal bacteria, said method comprising comparing a first amount of binding of an amino acid sequence as depicted in SEQ ID NO: 5 in the presence of said compound to a second amount of binding of an amino acid sequence as depicted in SEQ ID NO: 5 not in the presence of said compound; whereby a lower first amount of binding than said second amount binding indicates that said compound may induce said immune response in said mammal.
- 47. A method for diagnosing pneumococcal bacterial infection, said method comprising comparing the level of PPP as depicted in SEQ ID NO: 5, or fragments thereof, in suspect sample to the level of PPP as depicted in SEQ ID NO: 5, or fragments thereof, in a control sample, whereby a higher level of said Pneumo Protective Protein said suspect sample than the level of said Pneumo Protective Protein in said control sample indicates that said suspect sample comprises pneumococcal bacterial infection.
- 48. An antibody which binds to Streptococcus pneumoniae PPP.
- 49. An antibody as defined in claim 48, which selectively recognizes an amino acid sequence as depicted in SEQ ID NO: 5, or fragments thereof.
- 50. An antibody as defined in claim 48, which is chimeric.
- 51. An antibody as defined in claim 48, which is humanized.
- 52. An antibody as defined in claim 48, which is anti-idiotypic.
- 53. An antibody as defined in claim 48, which is conjugated to a pharmaceutically active compound.
- 54. An antibody as defined in claim 48, which is a monoclonal antibody.
- 55. An antibody as defined in claim 54, which is humanized.
- 56. An antibody as defined in claim 54, which is anti-idiotypic.
- 57. An antibody as defined in claim 54, which is conjugated to a pharmaceutically active compound.
- 58. A method for inducing an immune response in a mammal, said method comprising administering to said mammal an amount of an antibody as defined in claim 52 effective to induce an immune response in said mammal.
- 59. A method for inducing an immune response in a mammal, said method comprising administering to said mammal an amount of an antibody as defined in claim 56 effective to induce an immune response in said mammal.
- 60. A method for inducing an immune response in a mammal infected with pneumococcal bacteria, said method comprising administering to said mammal an amount of an antibody as defined in claim 53 effective to induce an immune response in said mammal.
- 61. A method for inducing an immune response in a mammal infected with pneumococcal bacteria, said method comprising administering to said mammal an amount of an antibody as defined in claim 57 effective to induce an immune response in said mammal.
PRIORITY
[0001] This application claims priority under 35 U.S.C. § 119 from U.S. Provisional Patent Application Serial No. 60/258,841, filed Dec. 28, 2000; which is hereby incorporated by reference in its entirety.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/US01/49650 |
12/28/2001 |
WO |
|